Transcription factors as targets of anticancer drugs

• Autorzy: Gniazdowski M. , Czyz M.
• Języki publikacji: EN

Abstrakty

EN

Several general and gene- and cell-selective transcription factors are required for specific transcription to occur. Many of them exert their functions through specific contacts either in the promoter region or at distant sequences regulating the initiation. These contacts may be altered by anticancer drugs which form non-covalent complexes with DNA. Covalent modifications of DNA by alkylating agents may prevent transcription factors from recognizing their specific sequences or may constitute multiple "unnatural" sites in DNA which attract the factors thus decreasing their availability in the cell. The anticancer drug-transcription factor interplay which is based on specific interactions with DNA may contribute to pharmacological properties of the former and provide a basis for the search for new drugs.

Słowa kluczowe

EN

intercalation; anticancer drug; transcription factor; actinomycin D; cisplatin; drug-DNA interaction; DNA; distamycin A

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1999
• Tom: 46
• Numer: 2
• Opis fizyczny: p.255-262

Twórcy

autor

Gniazdowski M.

• Medical University of Lodz, W.Lindleya 6, 90-131 Lodz, Poland, e-mail: [e-mail]

autor

Czyz M.

Bibliografia

• 1. Orphanides, G., Lagrange, T. & Reinberg, D. (1996) The general transcription factors of RNA polymerase II. Gene Develop. 10, 2657- 2683.
• 2. Hurst, H.C. (1996) Transcription factors as drug targets in cancer. Eur. J. Cancer 32A, 1857-1863.
• 3. Welch, J.J., Rauscher III, F.J. & Beerman, T.A. (1994) Targeting DNA-binding drugs to sequence-specific transcription factor • DNA complexes. J. Biol Chem. 269, 31051-31058.
• 4. Bellorini, M., Moncollin, V., D'lncalci, M., Mongelli, N. & Mantovani, R. (1995) Distamy- cin A and t&llimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res. 23, 1657-1663.
• 5. Sun, D. & Hurley, L.H. (1995) TBP binding to the TATA hox induces a specific downstream unwinding site that is targeted by pluramycin. Chem. Biol. 2, 457-469.
• 6. Vichi, P., Coin, F., Renaud, J.-P., Vermeulen, W., Hoeijmakers, J.H.J., Moras, D. & Egly, J.- M. (1997) Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/ TBP. EMBO J. 16, 7444-7456.
• 7. Broggini, M. & D'lncalci, M. (1994) Modula­tion of transcription factor-DNA interactions by anticancer drugs. Anti-Cancer Drug Design 9, 373-387.
• 8. Sun, D. & Hurley, L.H. (1994) Binding of Spl to the 21-bp repeat region of SV40 DNA: Ef­fect of intrinsic and drug-induced DNA bend­ing between GC boxes. Gene 149, 165-172.
• 9. Feriotto, G., Mischiati, C., Bianchi, N., Passa- dore, M. & Gambari, R. (1995) Binding of dis- tamycin and chromomycin to human immuno­deficiency type 1 virus DNA: A non-radio­active automated footprinting study. Eur. J. Pharmacol 290, 85-93.
• 10. Mac Leod, M.C., Powell, K.L. & Tran, N. (1995) Binding of the transcription factor, Spl, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis 16, 975-983.
• 11. Mac Leod, M.C., Powell, K.L., Kuzmin, V.A., Kolbanovskiy, A. & Geacintov, N.E. (1996) In­terference of benzo[a]pyrene diol epoxide- deoxyguanosine adducts in a GC box with binding of the transcription factor Spl. Mol Carcinogenesis 16, 44-52.
• 12. Bianchi, N., Passadore, M., Rutigliano, C., Fe­riotto, G., Mischiati, C. & Gambari, R. (1996) Targeting of the Spl binding sites of HIV-1 long terminal repeat with chromomycin. Bio- chem. Pharmacol 52, 1489-1498.
• 13. Taylor, A., Webster, K.A., Gustafson, T.A. & Kedes, L. (1997) The anti-cancer agent dista- mycin A displaces essential transcription fac­tors and selectively inhibits myogenic differ­entiation. Mol. Cell Biochem. 169, 61-72.
• 14. Czyz, M. & Gniazdowski, M. (1998) Actinomy- cin D specifically inhibits the interaction be­tween transcription factor Spl and its binding site. Acta Biochim. Polon. 45, 67-73.
• 15. Chiang, S.-Y., Azizkhan, J.C. & Beerman, T.A. (1998) A comparison of DNA-binding drugs as inhibitors of E2F1- and Spl-DNA complexes and associated gene expression. Biochemistry 37. 3109-3115.
• 16. Johnson, D.G., Coleman, A., Powell, K.L. & MacLeod, M.C. (1997) High-affinity binding of the cell cycle-regulated transcription factors E2F1 and E2f4 to benzo[
• 17. Trimmer, E.E., Zamble, D.B., Lippard, SJ. & Essigmann, J.M. (1998) Human testis-deter- mining factor SRY binds to the major DNA ad- duct of cisplatin and a putative target se­quence with comparable affinities. Biochemis­try 37, 352-362.
• 18. Bruice, T.C., Sengupta, D., Blasko, A., Chiang, S.-Y. & Beerman, T.A. (1997) A microgonotro- pen branched decaaza decabutylamine and its DNA and DNA/transcription factor interac­tions. Bioorgan. Med. Chem. 5, 685-692.
• 19. Chiang, S.-Y., Bruice, T.C., Azizkhan, J.C., Gawron, L. & Beerman, T.A. (1997) Targeting E2F1-DNA complex with microgonotropen DNA binding agents. Proc. NatL Acad. Sci. U.S.A. 94, 2811-2816.
• 20. Cutts, S.M., Parsons, P.G., Sturm, R.A. & Phillips, D.R. (1996) Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem. 271. 5422-5429.
• 21. Gray, P.J. (1995) Sulphur mustards inhibit binding of transcription factor AP2 in vitro. Nucleic Acids Res. 23, 4378-4382.
• 22. Chow, C.S., Whitehead, J.P. & Lippard, S.J. (1994) HMG domain proteins induce sharp bends in cisplatin-modified DNA. Biochemis­try 33, 15124-15130.
• 23. Cryer, J.E., Johnson, S.W., Engelsberg, B.N. & Billings, P.C. (1996) Analysis of HMG pro­tein binding to DNA modified with the anti­cancer drug cisplatin. Cancer Chemother. Pharmacol 38, 163-168.
• 24. Turchi, J.J., Li, M. & Henkels. K.M. (1996) Cisplatin-DNA binding specificity of calf high- mobility group 1 protein. Biochemistry 35, 2992-3000.
• 25. Patrick, S.M., Henkels, K.M. & Turchi, J.J. (1997) High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin- damaged DNA. Biochim. Biophys. Acta 1354, 279-290.
• 26.Ohndorf, U.-M., Whitehead, J.P., Raju, N.L. & Lippard, S.J. (1997) Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry 36, 14807-14815.
• 27. Hoffmann, J.S., Locker, D., Villani, G. & Leng, M. (1997) HMGl protein inhibits the translesion synthesis of the major DNA cis­platin adduct by cell extracts. J. Mol Biol 270, 539-543.
• 28. Dunham, S.U. & Lippard, S.J. (1997) DNA se­quence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. Biochemistry 36, 11428-11436.
• 29. Buhrmester, H., von Kries, J.P. & Stratling, W.H. (1995) Nuclear matrix protein ARBP recognizes a novel DNA sequence motif with high affinity. Biochemistry 34, 4108-4117.
• 30. Gale, E.F., Cundliffe, E., Reynolds, P.E., Rich­mond, M.H. & Waring, M J. (1981) Inhibitors of nucleic acid synthesis; in The Molecular Ba­sis of Antibiotic Action, pp. 258-401, Wiley, N.Y.
• 31. Gniazdowski, M. (1985) Molecular mechanism of inhibition of RNA synthesis. DNA- interacting inhibitors. Post. Biochemii 31, 53-86 (in Polish).
• 32. Denny, W.A. (1989) DNA-intercalating ligan- ds as anti-cancer drugs: Prospects for future design. Anti-Cancer Drug Design 4, 241-263.
• 33. Gniazdowski, M. & Cera, C. (1996) The effects of DNA covalent adducts on in vitro transcrip­tion. Chem. Rev. 96, 619-634.
• 34. Clark, S.J., Harrison, J. & Molloy, P.L. (1997) Spl binding is inhibited by mCpmCpG raethy- lation. Gene 195, 67-71.
• 35. Treiber, D.K., Zhai, X., Jantzen, H.-M. & Es- sigman, J.M. (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal tran­scription factor hUBF (human upstream bind­ing factor). Proc. Natl. Acad. Sci. U.S.A. 91, 5672-5676.
• 36. Paneva, E.G., Spassovska, N.C., Grancharov, K.C., Zlatanova, J.S. & Yaneva, J.N. (1998) In­teraction of histone HI with cis-platinum modified DNA. Z. Naturforsch. 53c, 135-138.
• 37. Chen, A.Y. & Lin, L.F. (1994) DNA topoi- somerases: Essential enzymes and lethal tar-gets. Annu. Rev. Pharmacol Toxicol 34,191- 218.
• 38. Henderson, D. & Hurley, L.H. (1995) Molccu lar struggle for transcriptional control. Nature Medicine 1, 525-527.
• 39. Jones, A. & Harris, A.L. (1998) New develop­ments in angiogenesis: A major mechanism for tumor growth and target for therapy. Can­cer J. 4, 209-217.
• 40. Denny, W. (1996) The design of selectively- activated prodrugs for cancer chemotherapy. Curr. Pharmaceutical Design 2, 281-294.